Eli Lilly and Walmart have partnered to offer in-store pickup of Zepbound (tirzepatide) single-dose vials through the LillyDirect platform by mid-November.
The collaboration marks the first time patients using LillyDirect, the company’s direct-to-consumer healthcare platform, will be able to access self-pay pricing for Zepbound vials at a retail pharmacy, according to an Oct. 29 news release.
LillyDirect’s self-pay pricing offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medications for obesity, with pricing ranging from $349 per month for the recommended 2.5 mg starting dose to $499 for all other strengths through the Zepbound Self Pay Journey Program.
The Zepbound vials will be available to patients with a valid, on-label prescription, regardless of insurance status, the release said.
In the second quarter of 2025, approximately 35% of new Zepbound prescriptions were filled through LillyDirect’s self-pay option. The company said it plans to expand access to its medicines through additional direct-to-consumer channels.
